Skip to main
  1. Stocks
  2. BeOne Medicines Ltd
  3. Forecast
ONC

ONC Stock Forecast & Price Target

ONC Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BeOne Medicines is favored because Brukinsa remains a durable market leader, generating about $1.39B in 3Q26 global revenue and roughly 74% of total revenue, while still expanding across indications and geographies despite competition from AbbVie and AstraZeneca. Its outlook is further supported by improving financial execution, including 3Q26 total revenue of $1.9B, diluted EPS of $3.28, and $5.87B in cash, alongside raised full-year guidance for revenue, operating income, and expenses. Beyond the core hematology franchise, management is advancing more than 50 drugs in clinical trials, with promising solid-tumor programs and next-wave assets like sonrotoclax and tacabrutideg creating additional long-term growth optionality.

Bears say

BeOne Medicines is exposed to meaningful fundamental risk because Brukinsa contributes 74% of total revenue, leaving the business highly dependent on one asset while newer products like Beqalzi and Tevimbra remain largely China-centric. The bearish thesis is reinforced by the possibility that sonro fails in Phase 3 and never reaches a registrational path, while other pipeline assets underperform and fail to differentiate in a crowded heme-onc market where AbbVie and AstraZeneca pressure the BTK space. With drug development, regulatory delays, competitive setbacks, and heavy pipeline cash burn all capable of impairing growth, the company’s valuation could be constrained even if commercial execution is solid.

ONC has been analyzed by 12 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BeOne Medicines Ltd and is not a guaranteed prediction by Public.com or investment advice.

ONC Analyst Forecast & Price Prediction

Get the latest ONC stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in ONC

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BeOne Medicines Ltd (ONC) Forecast

Analysts have given ONC a Buy based on their latest research and market trends.

According to 12 analysts, ONC has a Buy consensus rating as of Nov 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $429.08, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $429.08, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BeOne Medicines Ltd (ONC)


ONC Analyst Forecast & Price Prediction

Get the latest ONC stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in ONC

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover ONC stock data and trends